In February 2022 , Ngenla, a long-acting human growth hormone, was approved by the EU by Pfizer and Opko Health after being rejected by the FDA. This puts the two companies right behind Ascendis ...

and Skytrofa (lonapegsomatropin), a long-acting growth hormone for children with growth hormone deficiency. Yorvipath cuts the number of daily injections needed to treat hypoparathyroidism to one ...

Mo Vaughn fessed up to claims in the Mitchell Report that he used performance-enhancing drugs, nearly 20 years after its initial release.

The product now holds 45% of the U.S. long-acting growth hormone market. Mikkelsen announced the commercial launch of YORVIPATH in the U.S., with 908 unique patient prescriptions as of February 7 ...

For instance, Kexing is actively working on a new biological entity, GB08, a long-acting growth hormone in the form of an Fc-fusion protein. Meanwhile, the IND applications of GB18 indicated for ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...